Research & Development
-
Getty Images
A norovirus breakthrough?; another women’s healthtech haul
Yale researchers untangled norovirus RNA and Evvy just pulled in $40 million for precision medicine in women's health.
By PharmaVoice Staff • Sept. 18, 2026 -
Getty Images
A dark horse in the orexin race?
As the orexin competition heats up in the neuroscience space, Harmony Biosciences is developing an early-stage asset it believes could have an edge over rivals.
By Meagan Parrish • Sept. 18, 2026 -
Explore the Trendline➔
Getty Images
TrendlineEmerging biotech
After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.
By PharmaVoice staff -
Getty Images
Sling banks $123M for an experimental thyroid eye disease pill
A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.
By Gwendolyn Wu • Sept. 17, 2026 -
Michael M. Santiago via Getty Images
8 biotech IPO prospects testing investor appetite
Fresh filings and older proposals reveal different tests of clinical evidence, financing needs and readiness for public ownership.
By Sy Mukherjee • Sept. 17, 2026 -
Getty Images
‘Patients are not a renewable resource’: Rethinking rare disease R&D
Small patient communities face repeated demands for samples, data and time. The Speak Foundation’s founder explains how pharma can ease that burden while strengthening patients’ R&D involvement.
By Alexandra Pecci • Sept. 16, 2026 -
Getty Images
Where female participation in clinical trials has caught up — and where gaps remain
Getting more women into drug R&D remains critical for boosting health outcomes. But in some disease areas, pharma is still falling behind.
By Kelly Bilodeau • Sept. 16, 2026 -
Getty Images
3 KRAS drugs to watch as the field expands
Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark on the space.
By Kelly Bilodeau • Sept. 15, 2026 -
Permission granted by Cocrystal Pharma
Q&A // First 90 DaysCocrystal Pharma’s new CEO hopes to crack the norovirus code
James Sapirstein is bringing his Big Pharma chops to the clinical-stage company’s efforts to finally deliver an effective treatment for the vexing stomach bug.
By Alexandra Pecci • Sept. 15, 2026 -
Westy72 via Getty Images
PDUFA reauthorization offers a chance at clinical trial reforms. Will the US take it?
The reauthorization could give Congress the opportunity to help streamline clinical trials and accelerate drug research.
By Kelly Bilodeau • Sept. 14, 2026 -
howtogoto via Getty Images
Cancer still dominates pharma R&D. Obesity is gaining ground.
Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third of drugs target at least one rare disease.
By Alexandra Pecci • Sept. 11, 2026 -
Getty Images
mRNA cancer vaccines’ biggest barriers to market
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
By Alexandra Pecci • Sept. 10, 2026 -
Getty Images
5 questions that could determine Alzheimer’s next chapter
“The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?
By Kelly Bilodeau • Sept. 9, 2026 -
Getty Images
Merck pairs ADCs with Keytruda in women’s cancer push
The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda patent cliff.
By Kelly Bilodeau • Sept. 9, 2026 -
Scott Olson/Staff via Getty Images
Prediction markets are putting a price on pharma’s secrets. Here’s what companies need to know.
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners with access to sensitive information.
By Sy Mukherjee • Sept. 8, 2026 -
Justin Sullivan via Getty Images
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
By PharmaVoice Staff • Sept. 4, 2026 -
Joe Raedle via Getty Images
As measles outbreaks soar, where does drug R&D stand?
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up against a tense market environment.
By Alexandra Pecci • Sept. 4, 2026 -
Getty Images
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
By Jonathan Gardner • Sept. 3, 2026 -
Andrew Harnik via Getty Images
China’s clinical trial boom under scrutiny after 3 deaths come to light
Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths are reported.
By Kelly Bilodeau • Sept. 3, 2026 -
Getty Images
The hidden scale-out problem behind CAR-T’s growth
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.
By Sy Mukherjee • Sept. 1, 2026 -
Getty Images
Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.
By Alexandra Pecci • Aug. 31, 2026 -
Sponsored by ICON
Advances in risk assessment shift the calculus of early intervention trials for MASLD
How risk prediction is making early intervention trials in MASLD more feasible.
By Jolanta M. Wichary, MD, Vice President, Therapeutic Area Lead, Gastroenterology and Hepatology and Jack Martin, MD, FACC, Senior Director, Cardiovascular Therapeutics, Drug Development Solutions, ICON • Aug. 31, 2026 -
Alamy
New data could widen use of AstraZeneca, Amgen immune disease drug
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
By Delilah Alvarado • Aug. 28, 2026 -
Permission granted by Argenx
Q&A // First 90 DaysA single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
By Meagan Parrish • Aug. 28, 2026 -
Permission granted by GSK
Pharma’s new CEOs to watch
New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.
By Kelly Bilodeau • Aug. 27, 2026 -
Getty Images
3 takeover targets in immunology
Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.
By Kelly Bilodeau • Aug. 26, 2026
